貝康醫療-B:年度報告2023
Beacon Healthcare (2170.HK): Revenue and gross profit both increased by 50%, major acquisitions helped build the Chinese version of Vitrolife
Since Beijing first included 16 assisted reproduction programs in health insurance in June of last year, under the impetus of the National Health Insurance Administration, Guangxi, Inner Mongolia, Gansu and other places have followed suit and included some assisted reproduction programs in medical insurance, including egg retrieval, embryo culture, embryo transfer, sperm selection, diagnosis of embryonic genetic diseases (PGT-M), pre-implantation embryonic genetic testing (PGT-SR) for chromosomal diseases, and cell freezing. The overall reimbursement rate for these projects is as high as 50%-70%, and some projects can even be reimbursed twice.
BASECARE MEDICAL-B (02170. HK) Announces Annual Performance: Revenue and Gross Profit Growth of 48% and 53%, Completing Acquisition of BMX to Accelerate Globalization Layout
Basecare Medical-B (02170. HK) announced its annual performance. As of December 31, 2023, the group's revenue was RMB 208 million, a year-on-year increase of approximately 48%; The gross profit was RM
Beckon Medical-B (02170.HK) announced annual results: gross profit increased 48% and 53% year over year, completed the acquisition of Singapore BMX to accelerate global layout
Gelonghui, March 29丨Beacon Medical-B (02170.HK) announced its annual results. For the year ended December 31, 2023, the Group's revenue was RMB 208 million, up about 48% year on year; gross profit was RMB 91.351 million, up about 53% year on year; the Group's overall gross margin was 43.9%, which is basically the same as 42.2% for the year ended December 31, 2022. The increase in revenue was mainly due to (i) the steady increase in sales of PGT kits, (ii) the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and (iii) embryo incubators and
Beckon Medical-B (02170) announces 2023 results, shareholders' equity losses of about 192 million yuan, an increase of 56.27% year-on-year
According to the Zhitong Finance App, Beacon Medical-B (02170) announced its 2023 results, with revenue of about 208 million yuan, up 47.6% year on year; loss attributable to the company's equity shareholders was about 192 million yuan, an increase of 56.27% year on year; loss per share was 0.7 yuan. According to the announcement, the increase in revenue was mainly due to the steady increase in sales of PGT kits, the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and the increase in revenue from sales of consumables such as embryo incubators and culture medium.
BASECARE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Beacon Medical-B (02170.HK) will hold a board meeting on March 28 to approve the full year results
Gelonghui, March 18 | Beckon Medical-B (02170.HK) announced that the company will hold a board meeting on March 28, 2024 to adopt the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider the payment of a final dividend (if any).
In-depth layout of “AI+ Healthcare”, Beckon Healthcare (02170.HK) leads the wave of smart medical care
In recent years, with the continuous advancement of technology, the application of artificial intelligence (AI) in the medical field is showing unlimited potential. In an age where population issues are prominent, the combination of artificial intelligence and medical treatment may become a “good medicine” to alleviate the shortage of medical resources in our country.
BASECARE-B: 2023 INTERIM REPORT
Hong Kong Stock Concept Tracking | Policies to encourage childbearing are frequent in various regions, and the mother-child and assisted reproduction industries are expected to benefit (with concept stocks)
The increase in newborns will greatly increase demand throughout the mother and child industry chain, bringing investment opportunities for related industries and companies.
Hong Kong Stock Concept Tracking | Countries and regions intensively introduce policies to encourage the motherhood and child industry to rise above the wind (with concept stocks)
The special additional deduction standard for the care of infants under 3 was raised to 2,000 yuan per month.
Beckon Healthcare-B released interim results, revenue of 85.546 million yuan, up 24.76% year-on-year
Beckon Healthcare-B (02170) announced its interim results for the six months ended June 30, 2023. The group achieved revenue of RMB 85.546 million (same unit), an increase of 24.76% over the previous year; R&D expenses of RMB 63.724 million, an increase of 40% over the previous year; and losses attributable to equity shareholders of 61.369 million yuan, or 0.2 yuan per share.
Beckon Healthcare-B (02170) released interim results, with revenue of 85.546 million yuan up 24.76% year-on-year
Beckon Healthcare-B (02170) announced its interim results for the 6 months ended June 30, 2023. The group achieved...
BASECARE-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Beckon Healthcare-B (02170.HK) will hold a board meeting on August 30 to approve the interim results
Glonghui, August 18, 丨 Becon Medical-B (02170.HK) announced that the company will hold a board meeting on August 30, 2023 to review and approve the publication of the company and its subsidiaries' interim results announcements for the six months ended June 30, 2023, and consider recommending the payment of interim dividends (if any).
BASECARE-B: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Beckon Medical-B (02170) rose more than 8% in the afternoon and expects total revenue for the first half of the year to increase 15.7% to 28% year-on-year
The Zhitong Finance App learned that Becon Medical-B (02170) rose more than 8% in the afternoon. As of press release, it rose 8.72% to HK$3.24, with a turnover of HK$1,118 million. According to the news, Becon Healthcare announced that the group's total revenue for the first half of 2023 is expected to be around RMB 79.4 million to RMB 87.8 million, up 15.7% to 28.0% over the previous year, mainly due to sales of PGT-A kits and ultra-low temperature storage equipment. Gross profit for the first half of 2023 is expected to be around RMB 30.2 million to RMB 36.4 million, an increase of no more than 20.5% over the previous year. expects
Suzhou Basecare Medical's Expects Gross Profit to Jump Up To 20.5% in First Half
Suzhou Basecare Medical (HKG:2170) expects gross profit to increase up to 20.5% to between 30.2 million yuan and 36.4 million yuan in the six months ended June 30 from 30.2 million yuan a year earlier
[Company Yingxi] Beckon Medical-B (02170) expects medium-term total revenue to increase 15.7%-28.0% year on year
Beckon-B announced that the Group's total revenue for the six months ending June 30, 2023 is expected to be between RMB 79.4 million to RMB 87.8 million, an increase of 15.7% to RMB 28.0% from RMB 68.6 million for the six months ended June 30, 2022. The increase in Group revenue was mainly due to sales of PGT-A kits and ultra-low temperature storage equipment. The Group's gross profit for the six months ending June 30, 2023 is expected to be between RMB 30.2 million to RMB 36.4 million, up from RMB 30.2 million for the six months ended June 30, 2022
BASECARE-B: PROFIT ALERT
No Data